Amgen Inc. (NASDAQ:AMGN) [Trend Analysis] moved down reacts as active mover, shares a decrease -0.01% to traded at $155.55 and the percentage gap between open changing to regular change was -0.42%. Amgen (AMGN) released that the Kyprolis Global Economic Model (K-GEM)1 has been published in the Journal of Medical Economics showing that in the United States (U.S.), Kyprolis in combination with lenalidomide and dexamethasone (KRd) is cost-effective compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
The K-GEM demonstrated an incremental cost-effectiveness ratio of $107,250 per Quality-Adjusted Life Year (QALY). Kyprolis provides substantial value when its cost per QALY is contrasted against willingness-to-pay estimates of $150,000-$300,000 per QALY, which are cited as reasonable benchmarks for cancer in the U.S. The firm’s current ratio calculated as 5.00 for the most recent quarter. The firm past twelve months price to sales ratio was 5.29 and price to cash ratio remained 3.37. As far as the returns are concern, the return on equity was recorded as 25.70% and return on investment was 12.50% while its return on asset stayed at 10.00%. The firm has total debt to equity ratio measured as 1.20. The firm has 20-Day Simple Moving Average has
Great Basin Scientific, Inc. (NASDAQ:GBSN) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -15.97% to close at $2.00 with the total traded volume of 1.52 Million shares. Great Basin Scientific, Inc. (GBSN) released that it has priced a public offering of 3.16 million units at a public offering price of $1.90 per unit.
The Company expects that the gross proceeds of the offering of the units will be approximately $6 million. Each unit will consist of one share of common stock and one Series G warrant. Each Series G warrant will entitle the holder to acquire one share of common stock at an exercise price of $1.90 per share, subject to adjustment, for a period of five years following the date of issuance. The firm has institutional ownership of 7.90%, while insider ownership included 4.12%. Its price to sales ratio ended at 4.30. GBSN attains analyst recommendation of 3.00 with week performance of -23.95%.
Crestwood Equity Partners LP (NYSE:CEQP) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 2.45% to $21.73. Crestwood Midstream Partners LP, a wholly-owned subsidiary of Crestwood Equity Partners LP (CEQP), announced that CMLP has amended the terms of its previously announced cash tender offers to increase the aggregate purchase price from $250,000,000 to $312,000,800, exclusive of accrued interest, of the outstanding notes issued by CMLP and its wholly-owned subsidiary, set forth in the table below.
All other terms of the Tender Offers remain unchanged. The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 12, 2016 and the related Letter of Transmittal, and this press release is qualified in all respects by reference to such documents. The share price of CEQP attracts active investors, as stock price of week volatility recorded 5.54%. The stock is going forward to its 52-week low with 184.87% and lagging behind from its 52-week high price with -46.92%.